Metabolic health during a randomized controlled lifestyle intervention in women with PCOS.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
30 Nov 2021
Historique:
received: 23 06 2021
accepted: 28 10 2021
pubmed: 30 10 2021
medline: 15 12 2021
entrez: 29 10 2021
Statut: epublish

Résumé

Women with polycystic ovary syndrome (PCOS) have an increased risk of metabolic syndrome (MetS). Both PCOS and MetS are associated with excess weight. To examine the effect of a three-component lifestyle intervention (LSI) with or without short message service (SMS+ or SMS-, respectively) on the prevalence and severity of MetS and metabolic parameters, compared to care as usual (CAU). Randomized controlled trial. Women diagnosed with PCOS and a BMI >25 kg/m2 (n = 183) were either assigned to a 1-year three-component (cognitive behavioural therapy, diet, and exercise) LSI, with or without SMS support, or to CAU which provided weight-loss advice only. Main outcome measures included changes in the prevalence of MetS, the continuous MetS severity z-score (cMetS z-score), metabolic parameters, and the impact of weight loss. After 1 year, the decrease in the cMetS z-score was greater in the SMS+ group than the CAU group (-0.39, P = 0.015). The prevalence of MetS changed with -21.6% (P = 0.037), -16.5% (P = 0.190), and +7.0% (P = 0.509) in both LSI groups and CAU group, respectively. A post hoc analysis for both LSI groups combined vs CAU resulted in a MetS difference of -25.9% (P = 0.046). Moreover, weight loss per se resulted in significantly favourable effects on all metabolic parameters. This three-component LSI was more successful in improving metabolic health compared to CAU. Therefore, we recommend this intervention to women with PCOS and excess weight, provided that a clinically relevant weight loss is being pursued.

Identifiants

pubmed: 34714771
doi: 10.1530/EJE-21-0669
pii: EJE-21-0669
pmc: PMC8679850
doi:
pii:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

53-64

Références

Hum Reprod. 2013 Apr;28(4):979-86
pubmed: 23427235
Cochrane Database Syst Rev. 2019 Mar 28;3:CD007506
pubmed: 30921477
Nutrients. 2019 Sep 23;11(10):
pubmed: 31547562
Fertil Steril. 2017 Mar;107(3):788-795.e2
pubmed: 28089571
Fertil Steril. 2016 Feb;105(2):486-93
pubmed: 26551442
Diabetes Metab Syndr Obes. 2017 Feb 20;10:65-72
pubmed: 28255250
Endocrine. 2006 Aug;30(1):19-26
pubmed: 17185788
Diabetologia. 2017 Jul;60(7):1261-1270
pubmed: 28378033
Reprod Health. 2017 Mar 6;14(1):34
pubmed: 28264692
Hum Reprod. 2008 Mar;23(3):642-50
pubmed: 18158291
J Gynecol Obstet Hum Reprod. 2021 Jun;50(6):101894
pubmed: 32814159
Fertil Steril. 2018 Aug;110(3):364-379
pubmed: 30033227
Public Health Nutr. 2019 Sep;22(13):2419-2435
pubmed: 31262374
Obesity (Silver Spring). 2020 Nov;28(11):2134-2141
pubmed: 32969197
Fertil Steril. 2004 Jan;81(1):19-25
pubmed: 14711538
Obes Rev. 2019 Feb;20(2):339-352
pubmed: 30339316
Transl Res. 2017 May;183:57-70
pubmed: 28130064
Obes Manag. 2007 Apr;3(2):69-73
pubmed: 20436797
Int J Endocrinol. 2016;2016:3058393
pubmed: 27688754
Endocrine. 2019 May;64(2):220-232
pubmed: 30911997
Expert Rev Cardiovasc Ther. 2004 Mar;2(2):213-28
pubmed: 15151470
J Clin Endocrinol Metab. 2006 Nov;91(11):4237-45
pubmed: 16940456
Hum Reprod Update. 2006 Nov-Dec;12(6):673-83
pubmed: 16891296
Minerva Endocrinol. 2013 Sep;38(3):305-19
pubmed: 24126551
Hum Reprod. 2010 Feb;25(2):544-51
pubmed: 19910321
JAMA. 2001 May 16;285(19):2486-97
pubmed: 11368702
J Clin Endocrinol Metab. 2008 Feb;93(2):470-6
pubmed: 18056772
J Am Coll Cardiol. 2017 Mar 7;69(9):1204-1205
pubmed: 28254184
Steroids. 2014 Oct;88:36-43
pubmed: 24945113
Fertil Steril. 2014 Nov;102(5):1444-1451.e3
pubmed: 25239303
Metabolism. 2014 Feb;63(2):218-25
pubmed: 24290837
Diabetes Care. 2007 Sep;30(9):2381-7
pubmed: 17563336
Hum Reprod Update. 2012 Nov-Dec;18(6):618-37
pubmed: 22767467
Eur J Obstet Gynecol Reprod Biol. 2007 Aug;133(2):203-7
pubmed: 17207902
Hum Reprod. 2016 Dec;31(12):2841-2855
pubmed: 27664216

Auteurs

Alexandra Dietz de Loos (A)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus MC, Rotterdam, the Netherlands.

Geranne Jiskoot (G)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus MC, Rotterdam, the Netherlands.
Department of Psychiatry, Section Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, the Netherlands.

Annemerle Beerthuizen (A)

Department of Psychiatry, Section Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, the Netherlands.

Jan Busschbach (J)

Department of Psychiatry, Section Medical Psychology and Psychotherapy, Erasmus MC, Rotterdam, the Netherlands.

Joop Laven (J)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynaecology, Erasmus MC, Rotterdam, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH